OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2023-12-31-accounts

Charity registration number 1163211

Company registration number CE004367 (England and Wales)

PARKINSON'S EUROPE

(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) LEGAL AND ADMINISTRATIVE INFORMATION

Trustees G Boyle J M M Domingos P Perez Librero C P Likar A Moretti T Shaish A S Butler (Appointed 27 June 2023) B J Magennis (Appointed 27 June 2023) K Wouters (Appointed 27 June 2023) Key Personnel Rusell Patten Director General Dominic Graham Operations Director Lisa Wong Finance Manager Charity number 1163211 Company number CE004367 Registered office Lynwood House Crofton Road Orpington Kent BR6 8QE Independent examiner Louise Hallsworth, FCA Baxter & Co Chartered Certified Accountants Lynwood House, Crofton Road Orpington Kent BR6 8QE

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) CONTENTS

Page
Trustees' report 1 - 7
Independent examiner's report 8
Statement of financial activities 9
Balance sheet 10
Notes to the financial statements 11 - 19

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) FOR THE YEAR ENDED 31 DECEMBER 2023

The trustees present their annual report and financial statements for the year ended 31 December 2023.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's constitution, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019).

Objectives and activities

The trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake.

Research: a new workstream

Research Steering Group

To make sure the new Parkinson’s Europe research strategy truly reflects the voice of the Parkinson’s community, we created a Research Steering Group (RSG) in Q3 2022. The group represents our key stakeholders (people affected by Parkinson’s, healthcare professionals, Parkinson’s Europe Member Organisations and the treatment industry), and will focus and deliver on our research offer.

Research Strategy

The RSG’s initial work was to guide the creation of the Parkinson’s Europe Research Strategy, based on insights gathered from our Member Organisations and treatment industry partners about their patient involvement and engagement activities in the research space. The RSG then helped with the development and translation of the Research Strategy Executive Summary into nine languages.

The Research Strategy was then launched in Q2 2023 with a new webpage and a social media campaign, which achieved 11,500 impressions and 600 engagements.

Our Research Strategy will ensure all stakeholders have a clear understanding of Parkinson’s Europe’s aims and ambitions in the research space – and will be the foundation to deliver on our Strategic Goal 4.

For more information about our activities on research, please contact amelia@parkinsonseurope.org.

Parkinson’s Europe Engagement Network

Parkinson’s Europe recognised the need to reach more people across Europe in a strategic and constructive way, to share calls to action that would help us achieve our current and future strategic activities and support the many significant advancements for the Parkinson’s community that are continually taking place in different areas (such as research, advocacy and knowledge sharing).

Having secured funding from CRO company IQVIA in 2023, we developed the technical infrastructure to make the Parkinson’s Europe Engagement Network (PEN) possible. The PEN is an online network designed to connect people affected by Parkinson’s with opportunities they can actively take part in that will impact their future. People who sign up to the PEN will benefit by having opportunities they are interested in sent directly to them via email, according to their own interests and preferences.

In the development phase, we involved our stakeholders when discussing how the PEN would function; we then connected with all our volunteers and friends (a mix of organisations and individuals) to support the alpha and beta phases of testing of the network.

The PEN was launched in December 2023, and we have been actively promoting engagement since then. Opportunities shared with the PEN members in the initial weeks had a very high rate of interest and participation – supporting the delivery of our Strategic Goals 3 and 4.

For more information about the PEN, please contact amelia@parkinsonseurope.org.

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Our advocacy activities at the European level

Campaign advocating for a ban of glyphosate

In 2023, the licence for the use of glyphosate – a herbicide associated with a perceived higher risk of developing Parkinson’s – ended in the European Union (EU). A renewal process was started by a list of companies and led by the European Commission. To combat this plan, Parkinson’s Europe started an advocacy campaign calling for the glyphosate licence not to be renewed for another 10 years. Instead, we asked that the licence be extended for only one year, to allow time to carry out further independent scientific research on glyphosate’s safety.

Our campaign started in November 2023, involving a number of our Member Organisations and other Parkinson’s organisations, as well as other pan-European organisations (including PAN Europe and EFNA) and important KOLs from the medical and scientific world. Our stakeholders joined a Parkinson’s Europe-led pan-European campaign, and were provided information and lobbying materials that we developed such as information sheets, letter templates, social media content and press releases.

We also reached out to our online community via social media, news articles, press releases and social media infographics translated into six languages. The online campaign achieved:

Although glyphosate was re-approved for 10 years in late November 2023 by the European Commission, we will continue our efforts to lobby against glyphosate and seek to involve more and a broader range of stakeholders. This campaign work supports our Strategic Goals 2 and 3.

Parkinson’s Advocacy Group Forum

The treatment industry is a key stakeholder in the Parkinson’s community, and we therefore acknowledge the need to involve industry representatives in our political advocacy work.

In October 2023, we launched the Parkinson’s Advocacy Group (PAG) Forum, which brings together representatives of our Member Organisations as well as of our industry partners with the purpose of exploring political advocacy issues on which we could work together to find synergies and achieve win-win results for all parties.

The PAG Forum will be meeting regularly every three months. These meetings deliver great value both to Parkinson’s Europe, our members and our industry partners, in support of our Strategic Goal 3. For more information about our political advocacy activities, please contact russell@parkinsonseurope.org, fiona@parkinsonseurope.org or adrien@parkinsonseurope.org.

Our global reach, engagement and collaboration

World Parkinson’s Day 2023

World Parkinson’s Day (WPD) is one of Parkinson’s Europe’s key focuses, and for 2023 our key campaign objectives were:

  1. To support members and the wider Parkinson’s community to raise awareness of Parkinson’s via their own campaigns and activities

  2. To showcase and promote campaigns across the globe on our online map and social media campaign

  3. To gain support for World Parkinson’s Day to be officially recognised and observed as a global health day.

With our 2023 campaign, we aimed to primarily reach and engage with local, national, regional and international Parkinson’s organisations, as well as with global health organisations (such as the World Health Organisation, WHO). In addition, we also targeted individuals affected by Parkinson’s, influencers, the academic world and the industry.

We consistently involved and supported our Member Organisations throughout the planning and development of the campaign by:

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

On an individual level, anyone from the Parkinson’s community was able to join our call to raise the profile and increase the recognition of WPD across the world.

We produced a wide array of campaign communication materials (meeting updates, e-shots, social media posts, website updates, articles) to make sure all our partners and Members were aware of our plans and how to get involved. Our Members and all organisations involved benefited by having a platform to amplify their campaigns, which helped increase awareness of Parkinson’s in general – consistently with our Strategic Goals 2 and 3.

The figures below show the wide reach and engagement of our campaign:

World Parkinson Congress 2023

The World Parkinson Congress (WPC) is the only international Parkinson’s congress. The 2023 edition was held in Barcelona, Spain, and it saw a very high participation from the European Parkinson’s community – it was therefore a key event for Parkinson’s Europe to attend and be actively engaged with.

Parkinson’s Europe’s key goals from participating in the WPC were:

  1. Networking, engagement and increasing brand awareness

  2. Scientific, research and working group input

  3. Fundraising and engagement with the treatment industry

  4. To develop an advocacy plan to shape political thinking and engagement.

We supported our Member Organisations to attend the WPC, providing a €1,000 grant to seven organisations.

Members of the Parkinson’s Europe Team, including our Director General, were consistently involved in the WPC Leadership Forum and supporting Working Groups in the years leading up to the WPC, which meant that our organisation helped shape the Congress agenda and priority focus.

By attending the WPC, we achieved a significant level of engagement and interaction with all Parkinson’s community stakeholders – which will help us deliver all our four Strategic Goals:

For more information about our global stakeholder engagement activities, please contact fiona@parkinsonseurope.org.

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Online communication: delivering information and boosting Parkinson’s awareness

Our new website

The Parkinson’s Europe website had not had a major upgrade or restructure in several years, and we discovered it was no longer serving our audience in the best way – making it harder for users to find what they need, and affecting our SEO and traffic potential as a result.

As our website serves the whole Parkinson’s community and is a key part of our organisation’s brand and offering, we needed to develop a new platform to better meet the needs of our audience, increase our traffic, and help us communicate our core goals and campaigns in a more effective, up-to-date and impactful way.

The new website redevelopment kicked off in the summer of 2023, involving a web design agency, and launched in March 2024. Several of our industry partners sponsored this work and to whom we are most grateful.

Throughout the process, we carried out user surveys with people from the Parkinson’s community and key stakeholders to understand what they would like from the new website.

Our website is crucial to our 4 Strategic Goals, and the new website’s core features have been designed to support and enhance all of them. The new platform will be easier to navigate, and will include new functionalities such as:

Growing our social media presence

While enjoying a strong presence across all our core social media channels (Twitter/X, Facebook, LinkedIn and Instagram) for years, we wanted to accelerate our growth, engagement and overall impact on social media in 2023 to help us achieve all four Strategic Goals more widely, and deliver a positive impact by amplifying the voices and messages of people with Parkinson’s, our Member Organisations and our industry partners.

Activity took off in early 2023 and is currently ongoing. It has so far seen the active participation of:

All these stakeholders received significant exposure and engagement thanks to Parkinson’s Europe sharing their content to a growing and increasingly engaged audience.

Throughout 2023, our social media presence has grown significantly:

This growth has helped us boost our influence, as we were able to share and interact with key figures in 2023 such as the WHO (on World Parkinson’s Day), Paul McCartney (during the WPC), and Jeremy Paxman. It also helped boost our brand visibility by developing a consistent visual brand identity on social media.

For more information about our communication work, please contact laura@parkinsonseurope.org.

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Collaboration with the treatment industry

Parkinson’s Europe has a 30-year history of positive and fruitful collaboration with the treatment industry – a key stakeholder in the Parkinson’s community and a key player in the development of new treatments – and hopefully a cure – for Parkinson’s.

We often engage in important mutually beneficial partnership projects with our industry partners that aim to benefit the wider European Parkinson’s community. Below are two examples of successful projects we developed or concluded in 2023.

Parkinson’s Europe would like to sincerely thank our treatment industry partners for providing funding and support to our activities in 2023. For more information about our funding partners, please visit here. For more information about the projects below and our collaboration with the industry, please contact francesco@parkinsonseurope.org.

Multi-company working group on device-assisted therapies

Device-assisted therapies (DATs) have proven effective in improving the quality of life of people with Parkinson’s. Yet, testimonies and evidence increasingly tell us that not all people who may be suitable for these treatments receive them – which results in sub-optimal treatment and reduced quality of life for people with Parkinson’s, their families and caregivers.

Understanding this challenge, Parkinson’s Europe invited representatives of companies developing infusion pumps for levodopa, infusion pumps for apomorphine and deep brain stimulation devices to join a working group to a) explore common challenges and b) identify possible joint actions to improve people with Parkinson’s engagement with – and access to – DATs.

The working group firstly identified, mapped and prioritised specific challenges and pinch points in the pathway from the development of a DAT product to its distribution – pointing out common challenges along the way and identifying those that are considered as a priority and which fall within the work remit of Parkinson’s Europe. The group subsequently agreed to develop a knowledge-sharing resource aimed at people with Parkinson’s and their families to increase their awareness of DATs and empower them to discuss these therapy options with healthcare professionals. This work will continue in 2024.

This project is successfully bringing together different stakeholders to collaborate and share knowledge and good practices from their existing work areas (consistent with our Strategic Goal 2). It also aims to develop information resources aimed at people with Parkinson’s and their families (consistent with our Strategic Goal 1).

Survey on awareness of advanced Parkinson’s and treatment options

Evidence and testimonies show that a significant number of people with Parkinson’s may be at the advanced Parkinson’s stage but are not gaining access to, or information about, appropriate available treatment options. Topics such as symptom progression and decline in the effectiveness of oral medication are not always discussed with healthcare professionals – potentially resulting in sub-optimal treatments and reduced quality of life.

In 2021, Parkinson's Europe (in collaboration with industry partner Britannia Pharmaceuticals) launched an online multi-language survey focused on advanced Parkinson's and awareness about treatment options.

The results showed, among other things, that people with Parkinson’s experience variations in effects of oral medications, but lack expert advice. The full results were published in three scientific posters (presented at three international scientific congresses, in 2022 and 2023). In June 2023, a report aimed at the Parkinson’s community was published and disseminated widely, helping to increase the knowledge and awareness (both among people with Parkinson’s and healthcare professionals, consistent with our Strategic Goals 1 and 3) about advanced Parkinson’s diagnosis, management and treatment options.

Although this project is now concluded, the results of this survey are being used to inform further work carried out around the topic of advanced Parkinson’s and non-oral therapies.

In 2023, Parkinson’s Europe secured 20 funding partners. We would like to sincerely thank each and every one of them for providing funding and support to our activities in 2023. For more information about all of Parkinson’s Europe’s partners, please visit our partners web page."

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Financial review

During the year under review there was a decrease of £53,031 (2022: decrease of £245,750) on unrestricted funds and restricted funds introduced of £44,942.

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements. The Association's reserve policy is to hold reserves only to cover a period of 3 to 6 months administration costs. No additional reserves are intended to be held.

It is the policy of the charity that unrestricted funds which have not been designated for a specific use should be maintained at a level equivalent to between three and six month’s expenditure. The trustees consider that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charity’s current activities while consideration is given to ways in which additional funds may be raised. This level of reserves has been maintained throughout the year.

Structure, governance and management

The charity was established by a charitable trust deed on 25th April 1998 in Belgium and registered as a Charitable Incorporated Organisation in the UK on 19th August 2015.

The trustees have had regard to the Charity Commission's guidance on public benefit.

The trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

G Boyle V Clark (Resigned 27 June 2023) J M M Domingos L Graham (Resigned 27 June 2023) D J Lavender MBE (Resigned 27 June 2023) P Perez Librero C P Likar A Moretti T Shaish A S Butler (Appointed 27 June 2023) B J Magennis (Appointed 27 June 2023) K Wouters (Appointed 27 June 2023)

The following individuals were observer trustees during the period:

A Butler (Resigned June 2023) B Magennis (Resigned June 2023 B Morandi (Resigned June 2023) K Wouters (Resigned June 2023)

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

The trustees' report was approved by the Board of Trustees.

..............................

J M M Domingos

Trustee

Wednesday 26 June 2024 Date: .............................................

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) INDEPENDENT EXAMINER'S REPORT

TO THE TRUSTEES OF PARKINSON'S EUROPE

I report to the trustees on my examination of the financial statements of Parkinson's Europe (the charity) for the year ended 31 December 2023.

Responsibilities and basis of report

As the trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).

Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the charity’s financial statements carried out under section 145 of the Charities Act 2011 (the 2011 Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Since the charity’s gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of FCA, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Louise Hallsworth, FCA

Baxter & Co Chartered Certified Accountants Lynwood House, Crofton Road Orpington Kent BR6 8QE

Dated: .........................26 June 2024

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2023

Unrestricted
Restricted
funds
funds
2023
2023
Notes
£
£
Income from:
Donations and legacies
3
24,134
-
Charitable activities
4
455,211
98,241
Investments
5
478
-
Total income
479,823
98,241
Charitable activities
6
517,385
53,299
Net income/(expenditure)
(37,562)
44,942
Other recognised gains and losses:
Other gains/(losses)
12
(15,469)
-
Net movement in funds
(53,031)
44,942
Reconciliation of funds:
Fund balances at 1 January 2023
101,494
-
Fund balances at 31 December 2023
48,463
44,942		 Total
Unrestricted
funds
2023
2022
£
£
24,134
22,472
553,452
301,867
478
25
578,064
324,364
570,684
575,003
7,380
(250,639)
(15,469)
4,889
(8,089)
(245,750)
101,494
347,244
93,405
101,494

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) BALANCE SHEET

AS AT 31 DECEMBER 2023

Notes
Current assets
Debtors
13
Cash at bank and in hand
Creditors: amounts falling due within
one year
14
Net current assets
The funds of the charity
Restricted income funds
16
Unrestricted funds		 2023
£
56,726
221,438
278,164
184,759		 £
93,405
44,942
48,463
93,405		 2022
£
60,431
237,147
297,578
196,084		 £
101,494
-
101,494
101,494

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 December 2023.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the trustees on .........................Wednesday 26 June 2024

.............................. J M M Domingos Trustee

Company registration number CE004367 (England and Wales)

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies

Charity information

Parkinson Europe (formerly European Parkinson's Disease Association) is a Charitable Incorporated Organisation registered in the UK on 19 August 2015.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's Charity's trust deed, the Companies Act 2006, FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities not to prepare a Statement of Cash Flows.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors or grantors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies

(Continued)

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset’s use.

Irrecoverable VAT is charged against the expenditure heading for which it was incurred.

1.6 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities (if any). During the current and prior year there is no overdraft facility has been used on Parkinson's Europe's bank accounts.

1.7 Financial instruments

The charity has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity’s contractual obligations expire or are discharged or cancelled.

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies

(Continued)

1.8 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.9 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.10 Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2 Critical accounting estimates and judgements

In the application of the charity’s accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3 Income from donations and legacies

Unrestricted Unrestricted
funds funds
2023 2022
£ £
Donations and gifts 3,718 3,581
Membership fees 20,416 18,891
24,134 22,472

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

4 Income from charitable activities

Unrestricted
Restricted
funds
funds
2023
2023
£
£
Core income
298,307
98,241
Project income
154,146
-
Other income
2,758
-
455,211
98,241		 Total
Unrestricted
Restricted
funds
funds
2023
2022
2022
£
£
£
396,548
246,968
-
154,146
134,173
-
2,758
(79,274)
-
553,452
301,867
-		 Total
2022
£
246,968
134,173
(79,274)
301,867

5 Income from investments

Unrestricted Unrestricted
funds funds
2023 2022
£ £
Interest receivable 478 25
6 Expenditure on charitable activities
Charitable Charitable
activities activities
2023 2022
£ £
Direct costs
Member organisation and board meetings 9,181 15,636
Advocacy communication and project development 118,943 89,700
Funded projects 43,313 59,445
Other direct costs 7,140 407
Freelancer costs 111,258 180,742
289,835 345,930
Share of support and governance costs (see note 7)
Support 274,625 226,503
Governance 6,224 2,570
570,684 575,003
Analysis by fund
Unrestricted funds 517,385 575,003
Restricted funds 53,299 -
570,684 575,003

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

6 Expenditure on charitable activities

(Continued)

Included within share of supports costs are wages and salary costs amounting to £10,536 (2022: £13,654) directly attributable to member organisation, board meetings and advocacy in addition to the £17,582 (2022: £15,636) shown above, therefore the total spend for member organisation and board meetings in 2023 amounts to £28,118 (2022: £29,260).

7 Support costs allocated to activities

Staff costs
Technology costs
Bad debts
Bank charges
Bookkeeping costs
Other support costs
Travel costs
Insurance
Governance costs
Analysed between:
Charitable activities		 2023
£
262,481
3,319
192
314
3,960
2,685
560
1,114
6,224
280,849
280,849		 2022
£
210,412
2,944
241
256
3,886
3,831
3,857
1,076
2,570
229,073
229,073

8 Trustees

During the year, payments totalling £8,239 (2022: £30,877) were reimbursed or paid directly to two Trustees as follows;

Ms M E Graham (resigned 27/06/20230 received fees totalling £8,239 (2022: £30,195) in connection with her role as strategic advisor. The payments have been made in accordance with the charity's constitution and approved by the other trustees. A balance of £nil (2022: £2,634) is included within trade creditors as at the year end.

Ms T Shaish received a reimbursement of expenses in relation to a Charity Art project totalling £nil (2022: £682). The payments have been made in accordance with the charity's constitution and approved by the other trustees. No balance was outstanding at the year end.

9 Employees

The average monthly number of employees during the year was:

2023 2022
Number Number
Administration 6 6

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

9
Employees
Employment costs
Wages and salaries
Social security costs
Other pension costs		 (Continued)
2023
2022
£
£
242,071
195,857
15,162
11,912
5,248
2,643
262,481
210,412		 (Continued)
2023
2022
£
£
242,071
195,857
15,162
11,912
5,248
2,643
262,481
210,412
210,412

Last years employment costs were recharged to specific budget headings within the overall expenditure.

The number of employees whose annual remuneration was more than £60,000 is as follows:

2023 2022
Number Number
£60,000 - £70,0000 1 1

10 Key management personnel

The key management personnel of the charity comprise the Trustees and the key management team as listed on page 1. The total amount of key management personnel benefits (including employer pension contributions and employer national insurance contributions) received by key management personnel for their services to the charity was £139,882 (2022: £179,533).

11 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

12 Other gains and losses

Unrestricted Unrestricted
funds funds
2023 2022
Gains/(losses) upon: £ £
Foreign exchange 15,469 (4,889)

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

13 Debtors
2023 2022
Amounts falling due within one year: £ £
Trade debtors 56,726 58,392
Prepayments and accrued income - 2,039
56,726 60,431
14 Creditors: amounts falling due within one year
2023 2022
Notes £ £
Other taxation and social security 5,047 8,478
Deferred income 15 113,674 145,149
Trade creditors 27,125 20,013
Other creditors 17,267 16,924
Accruals 21,646 5,520
184,759 196,084
15 Deferred income
2023 2022
£ £
Other deferred income 113,674 145,149
Deferred income is included in the financial statements as follows:
2023 2022
£ £
Deferred income is included within:
Current liabilities 113,674 145,149
Movements in the year:
Deferred income at 1 January 2023 145,149 134,194
Released from previous periods (145,149) (134,194)
Resources deferred in the year 113,674 145,149
Deferred income at 31 December 2023 113,674 145,149

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

16 Restricted funds

The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used.

At 1 January Incoming Resources At 31
2023 resources expended December
2023
£ £ £ £
Website - 98,241 (53,299) 44,942

The specific purpose for which the Restricted Funds are to be applied is for the development of the New Website.

17 Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

At 1
General funds
Previous year:
At 1
General funds		 January
2023
Incoming
resources
Resources
expended
Gains and
losses
At 31
December
2023
£
£
£
£
£
101,494
479,823
(517,385)
(15,469)
48,463
January
2022
Incoming
resources
Resources
expended
Gains and
losses
At 31
December
2022
£
£
£
£
£
347,244
324,364
(575,003)
4,889
101,494

18 Analysis of net assets between funds

Unrestricted
Restricted
funds
funds
2023
2023
£
£
Fund balances at 31 December 2023 are represented by:
Current assets/(liabilities)
48,463
44,942
48,463
44,942		 Total
2023
£
93,405
93,405

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

18 Analysis of net assets between funds (Continued)
Unrestricted Restricted Total
funds funds
2022 2022 2022
£ £ £
Fund balances at 31 December 2022 are represented by:
Current assets/(liabilities) 101,494 - 101,494
101,494 - 101,494

19 Related party transactions

There were no disclosable related party transactions during the year (2022 - none), other than those disclosed within the trustees note in note 8.

PARKINSON’S EUROPE (FORMERLY EUROPEAN PARKINSON’S DISEASE ASSOCIATION)

KEY REPORTS AND NOTES IN EURO EQUIVALENT AT THE YEAR END

These pages do not form part of the statutory financial statements

PARKINSON’S EUROPE (FORMERLY EUROPEAN PARKINSON’S DISEASE ASSOCIATION) STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT (EURO)

FOR THE YEAR ENDED 31 DECEMBER 2023

Unrestricted
Unrestricted		 Restricted Restricted Unrestricted Unrestricted
funds funds funds funds funds funds
2023 2023 2023 2023 2022 2022
£ € £ € £ €
Income from:
Donations and legacies 24,134 27,849 - - 22,472 25,341
Charitable activities 455,211 525,284 98,241 113,364 301,867 340,400
Investment income 478 552 - - 25 28
Total income 479,823 553,685 98,241 113,364 324,364 365,769
Expenditure on:
Charitable activities 517,385 597,029 53,299 61,504 575,003 648,402
Net income / (expenditure) (37,562) (43,344) 44,924 51,860 (250,639) (282,633)
Other recognised gains
and losses
Other currency revaluation
gains or losses		 - 2,667 - - - (21,893)
Other gains / (losses) (15,469) (17,850) - - 4,889 5,513
Net movement in funds (53,031) (58,527) 44,942 51,860 (245,750) (299,013)
Fund balances at 1 January
2023		 101,494 114,450 - - 347,244 413,463
Fund balances at 31
December 2023		 48,463 55,923 44,942 51,860 101,494 114,450

This page does not form part of the statutory financial statements

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) BALANCE SHEET (EURO)

AS AT 31 DECEMBER 2023

Current assets
Debtors
Cash at bank and in hand
Creditors: amounts falling due within
one year
Net current assets
Income funds
Restricted funds
Unrestricted funds
Total funds		 2023
£
56,726
221,438
278,438
(184,759)
93,405
44,942
48,463
93,405		 2023
€
65,458
255,525
320,983
(213,200)
107,783
51,860
55,923
107,783		 2022
£
60,431
237,147
297,578
(196,084)
101,494
-
101,494
101,494		 2022
€
68,145
267,419
335,564
(221,114)		 2022
€
68,145
267,419
114,450
-
114,450
114,450

This page does not form part of the statutory financial statements

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) NOTES TO THE FINANCIAL STATEMENTS (EURO)

FOR THE YEAR ENDED 31 DECEMBER 2023

INCOME Unrestricted
funds		 Unrestricted
funds		 Restricted
funds		 Restricted
funds		 Unrestricted
funds		 Unrestricted
funds
2023 2023 2023 2023 2022 2022
£ € £ € £ €
Donations and
legacies
Donations and
gifts		 3,781 4,290 - - 3,581 4,038
Membership fees 20,416 23,559 - - 18,891 21,303
24,134 27,849 - - 22,472 25,341
Charitable
activities
Core income 298,307 344,227 98,241 113,364 246,968 278,493
Project income 154,146 177,874 - - 134,173 151,300
Other income 2,758 3,183 - - (79,274) (89,393)
455,211 525,284 98,241 113,364 301,867 340,400
Investment
income
Interest receivable 478 552 - - 25 28

This page does not form part of the statutory financial statements

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) NOTES TO THE FINANCIAL STATEMENTS (EURO)

FOR THE YEAR ENDED 31 DECEMBER 2023

EXPENDITURE Unrestricted
funds		 Unrestricted
funds		 Restricted
funds		 Restricted
funds		 Unrestricted
funds		 Unrestricted
funds
2023 2023 2023 2023 2022 2022
£ € £ € £ €
Charitable
activities
Direct costs
Member
organisation and 9,181 10,594 - - 15,636 17,632
board meetings
Advocacy
communication and
project		 76,604 88,396 42,339 48,856 89,700 101,150
development
Funded projects 43,313 49,980 - - 59,445 67,033
Other direct costs 7,140 8,239 - - 407 459
Freelancer costs 102,672 118,477 8,586 9,908 180,742 203,814
238,910 275,687 50,925 58,764 345,930 390,088
Support costs
Staff costs 260,138 300,182 2,343 2,704 210,412 237,271
Technology costs 3,288 3,794 31 36 2,944 3,320
Bad debts 192 222 - - 241 272
Bank charges 314 362 - - 256 289
Bookkeeping costs 3,960 4,570 - - 3,886 4,382
Other support costs 2,685 3,098 - - 3,831 4,320
Travel costs 560 646 - - 3,857 4,349
Insurance 1,114 1,285 - - 1,076 1,213
Governance costs 6,224 7,182 - - 2,570 2,898
278,475 321,342 2,374 2,739 229,073 258,314

This page does not form part of the statutory financial statements